CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race

Positive
AI Analysis

Summary

SK Biopharmaceuticals announced a $795 million deal with Biohaven Pharmaceutical to acquire its epilepsy program as SK enters the potassium channel opener market.

Importance:7/10
Sentiment:
0.60
acquisitionepilepsypotassium channel openerM&A
Related Companies

Read the original article

Published by yahoo_finance on August 27, 2026 2:40 PM

Read Original